Cardiovascular health
Cholesterol Ratios Explained: TC/HDL, LDL/HDL & Cardiovascular Risk
Your cholesterol ratio tells more about heart disease risk than total cholesterol alone. Learn what TC/HDL, LDL/HDL, non-HDL, and TG/HDL ratios mean, how AHA/ACC 2018 guidelines classify risk, and which lifestyle changes lower your numbers.
Free online tool
Cholesterol ratio
Why the Ratio Matters More Than Total Cholesterol Alone
Total cholesterol is a starting point, but it does not reveal how lipoprotein particles are distributed between protective HDL (high-density lipoprotein) and atherogenic apoB-carrying particles (LDL, VLDL, IDL, Lp(a)). Two people with identical total cholesterol of 220 mg/dL can carry radically different cardiovascular risk depending on their HDL level. The landmark MRFIT screening of 356,222 men documented a continuous, graded relationship between serum cholesterol and CHD mortality with no safe threshold (Stamler J et al., PMID 3773199), and Framingham follow-up demonstrated that lipoprotein ratios outperform total cholesterol in event prediction (Castelli WP et al., PMID 3773200).
The 2018 ACC/AHA Cholesterol Guideline (Grundy SM et al., PMID 30423391) and the 2019 ESC/EAS Dyslipidaemia Guideline (Mach F et al., PMID 31504418) both formally endorse non-HDL cholesterol and apoB-derived ratios as superior secondary targets, especially when triglycerides exceed 175 mg/dL or in patients with diabetes, obesity, or metabolic syndrome.
TC/HDL Ratio: Thresholds and Interpretation
The TC/HDL ratio divides total cholesterol by HDL. A lower number means more protective HDL per unit of total cholesterol. The AHA treats <5.0 as acceptable for most adults, but values below 3.5 are considered cardioprotective. In the Framingham cohort, a TC/HDL above 5.0 doubled CHD incidence versus a ratio below 3.5 at equivalent total cholesterol (Castelli WP, PMID 3773200).
TC/HDL Ratio Risk Categories
Optimal
< 3.5
Lowest cardiovascular risk. Excellent HDL protection relative to total cholesterol.
Desirable
3.5 – 5.0
Acceptable range. Monitor and maintain healthy lifestyle habits.
Borderline High
5.0 – 6.0
Moderately elevated risk. Lifestyle modifications and more frequent monitoring recommended.
High Risk
> 6.0
Significantly elevated cardiovascular risk. Consult a healthcare provider for management options.
LDL/HDL Ratio: Complementary Atherogenic Insight
The LDL/HDL ratio — the atherogenic index — isolates the LDL-versus-HDL balance and is particularly useful once treatment has begun, because it tracks the residual atherogenic burden after LDL-lowering therapy. Pooled analyses by Millán J et al. (PMID 19774217) confirmed LDL/HDL as a strong predictor of coronary disease events independent of LDL alone, with ratios above 3.5 conferring substantially elevated risk.
LDL/HDL Ratio Risk Classification
Optimal
< 2.0
Very low atherogenic risk. Strong HDL protection.
Normal
2.0 – 3.0
Average risk. Consistent with general population norms.
Borderline
3.0 – 3.5
Mildly elevated. Lifestyle changes are appropriate.
High Risk
> 3.5
Elevated atherogenic risk. Discussion with a physician is warranted.
Triglycerides/HDL Ratio: Insulin Resistance Marker
The TG/HDL ratio is a proxy for insulin resistance and the predominance of small, dense LDL particles — neither captured by a standard lipid panel. It is one of the most cost-effective surrogate markers of metabolic syndrome (Millán J, PMID 19774217). A TG/HDL above 3.0 (mg/dL) or 0.87 (mmol/L) flags excess hepatic VLDL output and is independently associated with increased coronary disease risk, particularly in women and in patients with normal LDL.
TG/HDL Ratio Interpretation (mg/dL)
Optimal
< 2.0
Healthy insulin sensitivity profile. Low small-dense LDL burden.
Borderline
2.0 – 3.0
Early metabolic stress. Address refined-carb intake and abdominal adiposity.
Elevated
3.0 – 4.0
Suggestive of insulin resistance and atherogenic dyslipidaemia.
High Risk
> 4.0
Strong marker of metabolic syndrome. Evaluate fasting glucose, HbA1c, blood pressure.
Non-HDL Cholesterol: The Modern Preferred Target
Non-HDL cholesterol (Total Cholesterol − HDL) captures every atherogenic apoB-containing particle — LDL, VLDL, IDL, and Lp(a). The 2018 ACC/AHA guideline (Grundy SM, PMID 30423391) and the 2019 ESC/EAS guideline (Mach F, PMID 31504418) both recommend non-HDL as the preferred secondary treatment target after LDL, especially when triglycerides are ≥175 mg/dL, when LDL is calculated rather than measured, or in diabetes and metabolic syndrome where small-dense LDL distorts the LDL measurement.
Non-HDL Cholesterol Targets (ACC/AHA 2018, ESC/EAS 2019)
Optimal
< 130 mg/dL (3.4 mmol/L)
Primary prevention target for average-risk adults.
Near optimal
130 – 159 mg/dL
Lifestyle optimisation recommended.
Borderline high
160 – 189 mg/dL
Assess 10-year ASCVD risk; consider statin if intermediate-high.
High / very high
≥ 190 mg/dL (4.9 mmol/L)
Severe hypercholesterolaemia — statin therapy typically indicated regardless of ASCVD score.
What Changes the Ratios: Diet, Exercise, Genetics
Roughly 40–60% of inter-individual variability in lipid profile is genetic — familial hypercholesterolaemia, ApoE polymorphisms, and CETP variants can drive ratios well outside lifestyle-modifiable ranges. The remaining 40–60% is highly responsive to modifiable factors: dietary fat composition, refined carbohydrate intake, body weight, abdominal adiposity, aerobic capacity, smoking status, sleep, and alcohol. Crucially, controlling cholesterol ratios alongside blood pressure delivers compounding benefit: the 2017/2018 ACC/AHA hypertension guideline (Whelton PK et al., PMID 29133356) demonstrated that simultaneous BP and lipid optimisation reduces ASCVD risk substantially more than either alone.
Evidence-Based Strategies to Improve Your Ratios
- Replace saturated fats with mono- and polyunsaturated fats (olive oil, nuts, avocado, fatty fish) — reduces LDL by 5–10% and modestly raises HDL.
- Increase soluble fibre (oats, legumes, psyllium, barley) — reduces LDL by 5–10 mg/dL at 5–10 g/day.
- Aerobic exercise ≥150 min/week of moderate intensity raises HDL by 3–6 mg/dL and lowers triglycerides 10–20%.
- Lose 5–10% body weight if overweight: can reduce triglycerides by 20% and substantially improve TC/HDL and TG/HDL.
- Quit smoking: HDL rises 5–10% within weeks; endothelial function recovers within months.
- Reduce refined carbohydrates, added sugars, and ultra-processed foods to cut hepatic VLDL output and TG/HDL ratio.
- Omega-3 fatty acids (EPA/DHA 2–4 g/day) reduce triglycerides 25–30% in moderate-to-severe hypertriglyceridaemia.
- Moderate alcohol (≤1 drink/day women, ≤2 men) may raise HDL slightly — but the net cardiovascular and oncologic balance favours less, not more.
Action Plan by Ratio Category
Optimal (TC/HDL < 3.5, LDL/HDL < 2.0)
Maintain current habits. Re-test lipids every 4–6 years if low ASCVD risk, or annually if known cardiovascular family history.
Desirable (TC/HDL 3.5–5.0)
Reinforce Mediterranean-style diet, ≥150 min/week aerobic activity, and weight maintenance. Re-test in 1–2 years.
Borderline (TC/HDL 5.0–6.0 or LDL/HDL 3.0–3.5)
Three to six months of intensive lifestyle modification, then re-test. Calculate 10-year ASCVD risk with your physician; discuss statin if risk is ≥7.5%.
High risk (TC/HDL > 6.0, LDL/HDL > 3.5, or non-HDL ≥ 190 mg/dL)
Consult your doctor promptly. Pharmacologic therapy (statin ± ezetimibe ± PCSK9 inhibitor) is typically indicated alongside lifestyle change, per ACC/AHA 2018 and ESC/EAS 2019 guidance.
Elevated TG/HDL (> 3.0)
Address insulin resistance: cut added sugars and refined starches, lose abdominal weight, screen fasting glucose/HbA1c and blood pressure. Consult your doctor if fasting triglycerides exceed 200 mg/dL.
When to seek medical advice
If your TC/HDL ratio exceeds 6.0, LDL/HDL exceeds 3.5, non-HDL cholesterol exceeds 190 mg/dL, or TG/HDL exceeds 4.0 despite lifestyle changes, consult your healthcare provider. Statin therapy or other lipid-lowering medication may be appropriate based on your 10-year ASCVD risk (ACC/AHA Pooled Cohort Equations) and personal/family history. This article is educational and does not replace individualised medical advice.
Use the CalcVita Cholesterol Ratio Calculator to instantly compute your TC/HDL, LDL/HDL, non-HDL cholesterol, and TG/HDL ratio with personalised ACC/AHA 2018 risk classification — in both mg/dL and mmol/L.
Sources
- Grundy SM et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. J Am Coll Cardiol. 2019;73(24):e285-e350. PMID 30423391.
- Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the MRFIT. JAMA. 1986;256(20):2823-8. PMID 3773199.
- Castelli WP et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Heart Study. JAMA. 1986;256(20):2835-8. PMID 3773200.
- Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. PMID 31504418.
- Whelton PK et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115. PMID 29133356.
- Millán J et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757-65. PMID 19774217.
